China
Africa
Explore chapters and articles related to this topic
Travoprost
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
A patient from Slovakia (age and sex not mentioned) presented with blepharoconjunctivitis. This individual reacted upon patch testing to eye drops containing travoprost. The active principle itself was not tested, but there were no reactions to the vehicle constituents and its preservative. After stopping the use of the eye drops and changing to a chemically different antiglaucoma drug, all complaints disappeared (2).
Cornea
Published in Mostafa Khalil, Omar Kouli, The Duke Elder Exam of Ophthalmology, 2019
Mostafa Khalil, Omar Kouli, Rizwan Malik
Herpes simplex virus (HSV) is a double-stranded DNA virus. Primary infection results in blepharoconjunctivitis. The virus usually remains latent in the trigeminal ganglion. Reactivation usually results in recurrent keratitis. Keratitis may affect the epithelial, stromal or endothelial layers of the cornea.
Medical Therapy for Glaucoma
Published in Neil T. Choplin, Carlo E. Traverso, Atlas of Glaucoma, 2014
Jennifer E. Williamson, Janet B. Serle
The numerous side effects of oral CAIs resulted in five decades of research, which culminated in the development and release of the first topically active CAI, dorzolamide 2% (Trusopt). Used three times daily, the drug is approximately equal in efficacy to betaxolol and slightly less effective than timolol. It is an excellent additive drug to topical β-adrenoreceptor antagonists, resulting in reductions in intraocular pressure reaching 35% from baseline. Many glaucoma specialists are of the opinion that twice-daily dosing of dorzolamide is sufficient when the drug is used as additive therapy. The drug is fairly well tolerated with minimal or no systemic side effects. The most common side effects are stinging and burning upon instillation, reported in up to 33% of patients, and bitter taste, which has been reported in up to 25% of patients. Allergic blepharoconjunctivitis (Figure 14.9) occurs in a small number of patients.
Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations
Published in Ocular Immunology and Inflammation, 2023
Shai Cohen, Hagar Olshaker, Naomi Fischer, Vicktoria Vishnevskia-Dai, David Hagin, Amir Rosenblatt, Dinah Zur, Zohar Habot-Wilner
Our cohort included two patients with ocular HSV post the BNT162b2 mRNA vaccine, and the literature review revealed five additional cases. Most of these patients were women (57%). The median age of the patients in our cohort was higher than of the published cases. All patients presented with symptoms of HSV infection up to 7 days following vaccination. To the best of our knowledge, our cases are the first reports of ocular HSV infection after the third vaccine dose and could be explained by the fact that Israel was the first country to administer the third booster dose. No patient in our cohort had a previous HSV infection whereas in the literature cohort most patients had previous keratitis. Overall, the most common presentation was keratouveitis. Our cohort included the first reported case presenting with blepharoconjunctivitis. All our HSV patients had complete resolution without any long-term complications, whereas two out of the five published cases had permanent complications: one with corneal haze (although final visual acuity was 20/20) and one with a corneal perforation and a residual corneal scar. There was also a lack of long-term data for the HSV published cases, and only one patient had a 4-week follow-up, whereas our patients had 4-month follow-up with no recurrence and a good final VA.
Therapeutic Effect of Intense Pulsed Light on Ocular Demodicosis
Published in Current Eye Research, 2019
XiaoZhao Zhang, Nan Song, Lan Gong
Blepharitis and blepharoconjunctivitis are characterized by inflammation of the outer eyelids and the conjunctiva that results in redness, swelling, prickle and stabbing pain, and also can lead to scarring of the eyelid and loss of proper eyelid function over time. Both of them are closely associated with Demodex infestation.1–3Demodex is a microscopic, elongated mite which is the common permanent ectoparasite of humans.4 The prevalence of Demodex infestation increases with age, reaching 84% of the population at age 60 years and 100% of those older than 70 years.5 Ocular manifestations of Demodex infestation include unexplained keratitis, superficial corneal vascularization, marginal infiltration, phlyctenule-like lesions, nodular corneal scarring, etc.6,7 It was proven that ocular demodicosis can be essentially diagnosed by the modified eyelash sampling and counting method and in vivo confocal microscopy (IVCM).8,9 However, there are only a few effective treatments at present.
Safety of dupilumab in patients with atopic dermatitis: expert opinion
Published in Expert Opinion on Drug Safety, 2021
Wojciech Francuzik, Aikaterina Alexiou, Margitta Worm
Although most of the DIOSD cases are considered mild to moderate side effects of dupilumab, cases of severe cicatrizing blepharoconjunctivitis have also been reported [14–17]. We also saw one patient with cicatrizing blepharoconjunctivitis in our department. A female with life-long severe AD who showed an outstanding positive response to dupilumab therapy developed keratoconjunctivitis after 6 weeks post loading dose. The inflammatory process became cicatrizing after 6 months of therapy. Combination therapy of corticosteroid and ciclosporin eye drops was able to alleviate the inflammation (unpublished data), but dupilumab had to be discontinued in this case.